Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104

Journal of Leukocyte Biology

Volumn 78, Issue 2, 2005, Pages 359-371

  Brando, Clara ^a,c   Mukhopadhyay, Sunil ^a,d   Kovacs, Eniko ^a   Medina, Rosa ^a,e   Patel, Pritesh ^a,f   Catina, Tracey L ^b   Campbell, Kerry S ^b   Santoli, Daniela ^a  

^a WISTAR INSTITUTE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c Department of Immunology   (United States)

^d Corning Inc ^*  (United States)

^e WUXI APPTEC   (China)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cancer therapy; Cytotoxic mechanisms; Regulatory receptors

Indexed keywords

CD3 ANTIGEN; FAS LIGAND; GRANZYME A; HLA A ANTIGEN; IMMUNOGLOBULIN RECEPTOR; IONOMYCIN; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; PHORBOL 13 ACETATE 12 MYRISTATE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CELL STRAIN K 562; CELL STRAIN U937; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOSTASIS; CYTOTOXIC T LYMPHOCYTE; DAUDI CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HAPLOTYPE; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; LEUKEMIA CELL LINE; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; PRIORITY JOURNAL; TUMOR CELL DESTRUCTION;

ADOPTIVE TRANSFER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD3; APOPTOSIS REGULATORY PROTEINS; CARCINOGENS; CELL DEGRANULATION; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMEDIATE-EARLY PROTEINS; IONOMYCIN; IONOPHORES; JURKAT CELLS; KILLER CELLS; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MONOMERIC GTP-BINDING PROTEINS; NEOPLASMS; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TETRADECANOYLPHORBOL ACETATE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; TUMOR NECROSIS FACTORS; U937 CELLS;

EID: 23044450852     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0604360     Document Type: Article

References (54)

1. Henkart, P. A. (1985) Mechanism of lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol. 3, 31-58.
2. Shresta, S., Pham, C. T. N., Thomas, D. A., Graubert, T. A., Ley, T. J. (1998) How do cytotoxic lymphocytes kill their targets? Curr. Opin. Immunol. 10, 581-587.
3. Lanier, L. L. (2001) On guard-activating NK cells. Nat. Immunol. 2, 23-27.
4. Trinchieri, G. (1989) Biology of natural killer cells. Adv. Immunol. 47, 187-376.
5. Godfrey, D. I., Hammond, K. J. L., Poulton, L. D., Smyth, M. J., Baxter, A. G. (2000) NKT cells: facts, functions and fallacies. Immunol. Today 21, 573-583.
6. Berke, G. (1994) The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects. Annu. Rev. Immunol. 12, 735-773.
7. Nagata, S., Golstein, P. (1995) The Fas death factor. Science 267, 1449-1456.
8. Beutler, B., van Huffel, C. (1994) Unraveling function in the TNF ligand and receptor families. Science 264, 667-668.
9. Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C. P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673-682.
10. Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., Ashkenazi, A. (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumour necrosis factor cytokine family. J. Biol. Chem. 271, 12687-12690.
11. Ashkenazi, A., Dixit, V. M. (1998) Death receptors: signaling and modulation. Science 281, 1305-1308.
12. Kägi, D., Lederman, B., Burki, K., Zinkernagel, R. M., Hengartner, H. (1996) Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu. Rev. Immunol. 14, 207-232.
13. O'Connor, R., Cesano, A., Lange, B., Finan, J., Nowell, P. C., Clark, S. C., Raimondi, S. C., Rovera, G., Santoli, D. (1991) Growth factor requirements of childhood acute T-lymphoblastic leukemia: correlation between presence of chromosomal abnormalities and ability to grow permanently in vitro. Blood 77, 1534-1545.
14. Cesano, A., Santoli, D. (1992) Two unique human leukemic T-cell lines endowed with a stable cytotoxic function and a different spectrum of target reactivity: analysis and modulation of their lytic mechanisms. In Vitro Cell. Dev. Biol. 28A, 648-656.
15. Cesano, A., Santoli, D. (1992) Inducible expression of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-α, and interferon-γ in two human cytotoxic leukemic T-cell lines. In Vitro Cell. Dev. Biol. 28A, 657-662.
16. Cesano, A., Visonneau, S., Clark, S. C., Santoli, D. (1993) Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL-12. J. Immunol. 151, 2943-2957.
17. Cesano, A., Visonneau, S., Cioe, L., Clark, S. C., Rovera, G., Santoli, D. (1994) Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach. J. Clin. Invest. 94, 1076-1084.
18. Cesano, A., Visonneau, S., Santoli, D. (1995) Treatment of experimental glioblastoma with a human major histocompatibility complex nonrestricted cytotoxic T cell line. Cancer Res. 55, 96-101.
19. Cesano, A., Visonneau, S., Pasquini, S., Rovera, G., Santoli, D. (1996) Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia. Cancer Res. 56, 4444-4452.
20. Visonneau, S., Cesano, A., Torosian, M., Santoli, D. (1997) Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) mice. Clin. Cancer Res. 3, 1491-1500.
21. Cesano, A., Visonneau, S., Rovera, G., Santoli, D. (1997) Synergistic effects of adriamycin and TALL-104 cell therapy against a human gastric carcinoma in vivo. Anticancer Res. 17, 1887-1892.
22. Cesano, A., Visonneau, S., Santoli, D. (1998) TALL-104 cell therapy of human solid tumors implanted in immunodeficient (SCID) mice. Anticancer Res. 18, 2289-2295.
23. Cesano, A., Visonneau, S., Tran, T., Santoli, D. (1999) Biodistribution of human MHC non-restricted TALL-104 killer cells in healthy and tumor-bearing mice. Int. J. Oncol. 14, 245-251.
24. Cesano, A., Wortman, J. A., Pourdehnad, M., Visonneau, S., Mozley, D., Bhatnagar, A., Alavi, A., Santoli, D. (1999) Effects of development of host immunity on the biodistribution of xenogeneic MHC non-restricted cytotoxic T cells: implications for adoptive cell therapy of cancer. Int. J. Oncol. 14, 233-244.
25. Geoerger, B., Tang, C. B., Cesano, A., Visonneau, S., Marwaha, S., Judy, K. D., Sutton, L. N., Santoli, D., Phillips, P. C. (2000) Antitumor activity of a human cytotoxic T-cell line (TALL-104) in brain tumor xenografts. Neuro-oncol. 2, 103-113.
26. Kruse, C. A., Visonneau, S., Kleinschmidt-DeMasters, B. K., Gup, C. J., Gomez, G. G., Paul, D. B., Santoli, D. (2000) The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy. Cancer Res. 60, 5731-5739.
27. Cesano, A., Visonneau, S., Jeglum, K. A., Owen, J., Wilkinson, K., Garner, K., Reese, L., Santoli, D. (1996) Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors. Cancer Res. 56, 3021-3029.
28. Visonneau, S., Cesano, A., Tran, T., Jeglum, K. A., Santoli, D. (1997) Successful treatment of canine malignant histiocytosis with the human major histocompatibility complex non-restricted cytotoxic T cell line TALL-104. Clin. Cancer Res. 3, 1789-1797.
29. Visonneau, S., Cesano, A., Jeglum, K. A., Santoli, D. (1999) Adjuvant treatment of canine osteosarcoma with the human cytotoxic T cell line TALL-104. Clin. Cancer Res. 5, 1868-1875.
30. Visonneau, S., Cesano, A., Jeglum, K. A., Santoli, D. (1999) Adoptive therapy of canine metastatic mammary carcinoma with the human MHC non-restricted cytotoxic T-cell line TALL-104. Oncol. Rep. 6, 1181-1188.
31. Visonneau, S., Cesano, A., Porter, D. L., Luger, S. L., Schuchter, L., Kamoun, M., Torosian, M. H., Duffy, K., Stadtmauer, E. A., Santoli, D. (2000) Phase 1 trial of TALL-104 cells in patients with refractory metastatic breast cancer. Clin. Cancer Res. 6, 1744-1754.
32. Cesano, A., Visonneau, S., Cioe, L., Clark, S. C., Santoli, D. (1995) Effects of lethal irradiation and cyclosporin A treatment on the growth and tumoricidal activity of a T cell clone potentially useful in cancer therapy. Cancer Immunol. Immunother. 40, 139-151.
33. Gong, J. H., Maki, G., Klingemann, H. G. (1994) Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8, 652-658.
34. Ugolini, S., Vivier, E. (2001) Multifaceted roles of MHC class I and MHC class I-like molecules in T cell activation. Nat. Immunol. 2, 198-200.
35. Exley, M., Porcelli, S., Furman, M., Garcia, J., Balk, S. (1998) CD161 (NKR-P1A) costimulation of CD1d-dependent activation of human T cells expressing invariant V α 24 J α Q T cell receptor α chains. J. Exp. Med. 188, 867-876.
36. + T cells in HIV-1-infected patients with progressing disease. J. Immunol. 162, 7563-7568.
37. Darmon, A., Page, L. J., Griffiths, G. M. (2000) Methods for detecting lytic granules in natural killer cells. Methods Mol. Biol. 121, 145-153.
38. Kataoka, T., Shinohara, S., Takayama, H., Takaku, K., Kondo, S., Yonehara, S., Nagai, K. (1996) Concanamycin A, a powerful tool for characterization and estimation of contribution of perform- and Fas-based lytic pathways in cell-mediated cytotoxicity. J. Immunol. 156, 3678-3686.
39. Di Pietro, R., Santavenere, E., Centurione, L., Stuppia, L., Centurione, M. A., Vitale, M., Rana, R. (1997) TNF-α-induced apoptosis in Daudi cells: multiparametric analysis. Cytokine 9, 463-470.
40. Gomez, G. G., Read, S. B., Gup, C. J., Gershcenson, L. E., Winston, K. R., Santoli, D., Kruse, C. A. (2002) Interactions of the allogeneic leukemic TALL-104 T cell line with human malignant brain tumors. Proc. Am. Assoc. Cancer Res. 43, 915.
41. Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M. C., Biassoni, R., Moretta, L. (2001) Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19, 197-223.
42. Campbell, K. S., Cella, M., Carretero, M., Lopez-Botet, M., Colonna, M. (1998) Signaling through human killer cell activating receptors triggers tyrosine phosphorylation of an associated protein complex. Eur. J. Immunol. 28, 599-609.
43. Sivori, S., Vitale, M., Morelli, L., Sanseverino, L., Augugliaro, R., Bottino, C., Moretta, L., Moretta, A. (1997) p46, a novel natural killer cell-specific surface molecule which mediates cell activation. J. Exp. Med. 186, 1129-1136.
44. Cantoni, C., Bottino, C., Vitale, M., Pessino, A., Augugliaro, R., Malaspina, A., Parolini, S., Moretta, L., Moretta, A., Biassoni, R. (1999) NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J. Exp. Med. 189, 787-795.
45. Biassoni, R., Pessino, A., Bottino, C., Pende, D., Moretta, L., Moretta, A. (1999) The murine homologue of the human NKp46, a triggering receptor involved in the induction of natural cytotoxicity. Eur. J. Immunol. 29, 1014-1020.
46. Sivori, S., Pende, D., Bottino, C., Marcenaro, E., Pessino, A., Biassoni, R., Moretta, L., Moretta, A. (1999) NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur. J. Immunol. 29, 1656-1666.
47. Dohring, C., Scheidegger, D., Samaridis, J., Cella, M., Colonna, M. (1996) A human killer inhibitory receptor specific for HLA-A. J. Immunol. 156, 3098-3101.
48. Jang, Y. J., Park, K. S., Chung, H. Y., Kim, H. I. (2003) Analysis of the phenotypes of Jurkat clones with different TRAIL sensitivities. Cancer Lett. 194, 107-117.
49. Heller, R. A., Krönke, M. (1994) Tumor necrosis factor receptor-mediated signaling pathways. J. Cell Biol. 126, 5-9.
50. Vitale, M., Bottino, C., Sivori, S., Sanseverino, L., Castriconi, R., Marcenaro, E., Augugliaro, R., Moretta, L., Moretta, A. (1998) NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J. Exp. Med. 187, 2065-2072.
51. Sivori, S., Falco, M., Marcenaro, E., Parolini, S., Biassoni, R., Bottino, C., Moretta, L., Moretta, A. (2002) Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation. Proc. Natl. Acad. Sci. USA 99, 4526-4531.
52. Parolini, S., Bottino, C., Falco, M., Augugliaro, R., Giliani, S., Franceschini, R., Ochs, H. D., Wolf, H., Bonnefoy, J. Y., Biassoni, R., Moretta, L., Notarangelo, L. D., Moretta, A. (2000) X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J. Exp. Med. 192, 337-346.
53. Hansasuta, P., Dong, T., Thananchai, H., Weekes, M., Willberg, C., Aldemir, H., Rowland-Jones, S., Braud, V. M. (2004) Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur. J. Immunol. 34, 1673-1679.
54. Pende, D., Biassoni, R., Cantoni, C., Verdiani, S., Falco, M., di Donato, C., Accame, L., Bottino, C., Moretta, A., Moretta, L. (1996) The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer. J. Exp. Med. 184, 505-518.